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Abstract: Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by occlusion of
bilateral internal carotid and intracerebral arteries with the compensatory growth of fragile small
vessels. MMD patients develop recurrent infarctions in the basal ganglia and subcortical regions.
Symptoms include transient ischemic attack or stroke, seizures, and headaches, which may occur
suddenly or in a stepwise progression. Mutations in Ring Finger Protein 213 (RNF213), a Zinc ring
finger protein, have been identified in some MMD patients but the etiology of MMD is still largely
unknown. To gain insight into the pathophysiology of MMD, we characterized the impact of the
RNF213 mutations on plasma protein and RNA profiles. Isobaric tags for relative and absolute
quantitation and proximity extension assay were used to characterize the plasma proteome. Next
generation sequencing-based small RNAseq was used to analyze the cell-free small RNAs in whole
plasma and RNA encapsulated in extracellular vesicles. The changes of miRNAs and proteins
identified are associated with signaling processes including angiogenesis and immune activities
which may reflect the pathology and progression of MMD.
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1. Introduction
Moyamoya disease (MMD) is a rare disorder first described in 1969 in Japanese patients [1] and
the majority of cases are from Eastern Asian descent. MMD is characterized by bilateral stenosis of
internal carotid arteries (ICAs) with frequent involvement of anterior and middle cerebral arteries.
The stenotic ICAs in MMD patients show thickening of intima, proliferation of smooth muscle cells,
and prominently tortuous and duplicated internal elastic lamina [2,3]. To compensate for the occlusion,
a large number of tiny and weak vessels are overgrown with the appearance of a “puff of smoke”
(termed moyamoya in Japanese) under conventional angiography. There are two major categories of
symptoms: ischemic attacks (stroke, reversible ischemic neurological deficits, and seizure) and the
deleterious consequences of the compensatory mechanism due to ischemia (hemorrhage from the
fragile collateral vessels and headache from dilated transdural collaterals) [4,5]. Several genetic loci
have been linked to MMD and mutations in RNF213 [6,7] and ACTA2 [8] genes have been identified in
some patients, but the etiology of disease is still unclear.
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Since the MMD pathologies are associated with blood vessels, characterizing the molecular
changes of plasma in patients with MMD may yield insights into the disease. For example, the process
of compensatory revascularization is associated with increased inflammatory signals and angiogenic
factors in blood including hypoxia-inducible factor-1, vascular endothelial growth factor (VEGF),
fibroblast growth factor (FGF) 2, transforming growth factors, matrix metalloproteinases (MMPs),
and granulocyte-macrophage colony-stimulating factor (GM-CSF, CSF2) [9–14].
In addition to proteins, blood also contains cell-free RNAs, especially microRNA (miRNA).
Recently, cell-free miRNA, a class of short noncoding regulatory RNA, have been harnessed as
biomarkers for various physiopathological conditions. For example, miR-122 levels in circulation are
an indicator for liver diseases [15], and concentration changes of miR-208 and miR-499 are associated
with heart conditions [16,17]. These cell-free circulating miRNAs are either bound to RNA binding
proteins, such as Nucleophosmin 1 (NPM1) or Argonaute 2 (Ago2) [18,19], or lipoproteins, such as
high-density lipoprotein (HDL) or low density lipoprotein (LDL) [20], or encapsulated into extracellular
vesicles (EVs) to evade RNase degradation [21,22]. EVs in circulation may play a role in cell–cell
communication [23]. Therefore, characterizing the molecular content in EVs is of great interest.
Here, we employ isobaric tags for relative and absolute quantitation (iTRAQ), a global proteome
profiling approach and a modified enzyme-linked immunosorbent assay (ELISA) called proximity
extension assay (PEA) technology [24] (Olink proteomics, Uppsala, Sweden) to characterize the impact
of MMD on plasma proteome. In addition, we used an in-house developed small RNA library
construction protocol to characterize the cell-free miRNAs, in whole plasma, EVs (miRNA inside of
EVs) and EV-depleted plasma (miRNA outside of EVs) that may provide insights into the perturbed
molecular processes involved in MMD. Comparing the miRNA profiles between EVs and EV-depleted
plasma also allowed us to determine the distribution of specific miRNA between in and outside of EVs.
To our knowledge, this is the first comprehensive characterization of circulating miRNA and proteins,
as well the distribution of circulating miRNA inside and outside of EVs in MMD patients.
2. Materials and Methods
2.1. Ethics Statement and Patient Information
This study was approved by the Research Ethics Board of National Taiwan University Hospital
(201506040RINB) and conducted according to the principles of the Declaration of Helsinki. Blood
samples were collected from patients who had been diagnosed with MMD and healthy controls. All
patients provided written informed consent to participate in this study. The information of study
participants is listed in Table S1.
This study included 7 MMD patients who carry a mutated RNF213 (MMD/RNF213+), 5 patients
without RNF213 mutation (MMD/RNF213-), and 12 controls. The clinical presentation of these patients
has been described previously [25]. The controls included 6 parents of MMD patients and 6 siblings.
2.2. Plasma Preparation and Extracellular Vesicle (EV) Isolation
MMD patient blood was collected from patients into K2-EDTA blood collection tubes after the
EDAS surgery. The control blood samples were collected during the patient’s first clinic visit. The blood
was centrifuged at 1000× g for 10 min at 4 ◦C and the supernatant (plasma) was transferred to a new
tube and centrifuged at 2500× g for 15 min. The plasma was then aliquoted into smaller polypropylene
tubes and stored at −80 ◦C. Prior to EV isolation or RNA extraction, plasma was spun at 10,000× g for
15 min at 4 ◦C. EVs were isolated from 200 µL of plasma using size exclusion chromatography (SEC)
columns (iZON qEV, Cambridge, MA, USA) with de-gassed 1× PBS (pH 7.2, Gibco, Grand Island, NY,
USA). The protocol for EVs and EV-depleted plasma preparation was described previously [26].
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2.3. Isolation of RNA and Small RNA Sequencing Library Construction
RNA was isolated from plasma, corresponding EVs and EV-depleted plasma samples using
miRNeasy Micro Kit (Qiagen, Germantown, MD, USA). The quality and quantity of the RNA
were evaluated with the Agilent 2100 Bioanalyzer (Santa Clara, CA, USA) and NanoDrop 1000
spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Small RNA sequencing libraries were
generated using a modified library construction protocol [27]. Modifications include adding four
random nucleotides at the appropriate end of the adapters to reduce ligation-associated bias, the use
of higher adapter concentrations, and increased amount of polyethylene glycol in the ligation steps.
In addition, two rounds of size selection steps are performed, following each amplification step,
to reduce the adapter dimer. Individual library concentrations were measured using the NEBNext
Library Quant Kit (New England Biolabs, Ipswich, MA, USA) and pooled to a final concentration of
2 nM then sequenced using the NEXTseq DNA sequencer (Illumina, San Diego, CA, USA).
2.4. Small RNAseq Data Analysis and Verification
The sequencing results were analyzed using sRNAnalyzer (http://srnanalyzer.systemsbiology.
net/) [28], which contains three major components: pre-processing, mapping, and results summarization.
In the pre-processing step, the adaptor sequences used in the library construction were trimmed
and the low-quality sequences were removed. The processed sequences were then mapped against
various databases. A detectable miRNA species is defined as having at least 10 mapped reads with no
mismatch allowed in at least 50% of the samples.
Taqman miRNA Assays were used to verify the concentration changes of specific miRNA identified
by next generation sequencing (NGS). In brief, RNA (2 µL) from individual samples was reverse
transcribed with the TaqMan microRNA RT kit (Thermo Fisher, Waltham, MA, USA). Real time qPCR
was performed using the BioRad CFX96 Touch real-time thermocycler (BioRad, Hercules, CA, USA)
with the following condition: 95 ◦C for 10 min followed by 40 cycles of amplification at 95 ◦C for 15 s
and 60 ◦C for 60 s. Hsa-miR-16-5p was used to normalize the results due to its high concentration and
low variation in plasma.
2.5. Plasma Protein Analysis
Global plasma proteome changes associated with MMD were measured using isobaric tags for
relative and absolute quantitation (iTRAQ) (Table S1). In brief, the 14 most abundant plasma proteins
were removed with a human Mars14 LC column (Agilent, CA, USA). The flow-through fractions
of each sample were collected and concentrated, and the protein concentrations were determined
by bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA). Proteins were digested with trypsin
following a 2,2,2-Trifluoroethanol (TFE)-denaturation and desalted on Oasis C18 cartridges (Waters,
Milford, MA, USA) before iTRAQ labeling. Approximately 60 µg of tryptic peptides from each sample
was labeled with one of the eight isobaric isotopic labeling reagents (8-plex iTRAQ, tag m/z 113, 114,
115, 116, 117, 118, 119 and 121 (AB SCIEX, Framingham, MA, USA) on N-termini and lysine residues.
Samples were combined and fractionated using a high-pH reverse-phase HPLC into 12 fractions.
iTRAQ-labeled samples were analyzed on a Q Exactive™ Plus Hybrid Quadrupole-Orbitrap mass
spectrometer. Acquired data were processed in Trans Proteomic Pipeline (TPP) (V4.8) including
PeptideProphet and ProteinProphet. The data were searched using the Open Mass Spectrometry
Search Algorithm (OMSSA) [29] against an International Protein Index (IPI) human database (version
3.87) with the addition of decoy sequences. Libra, an in-house script, was performed to extract ratios
of isobaric tags in MS/MS spectra. The threshold of minimum intensity for isobaric tags was set at
20. Mass tolerance was 0.1 Da. All ratios were normalized to one common channel in both iTRAQ
runs. Only proteins with more than 2 unique peptides identified and quantified in all channels were
included. Ratios for each protein were reported as significantly different if they showed a more than
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50% change of concentration (vs. average of normal controls) with a p-value of <0.05 from a two-tailed
student’s t-test.
A panel of 92 immune response-related proteins (Table S2) were measured using PEA following
the manufacturer’s protocol (Olink Proteomics, Uppsala, Sweden). Briefly, 1 µL of plasma sample
was added to each well of an incubation plate containing 3 µL of incubation mix and then incubate
the plate at 4 ◦C overnight to allow antibody to bind with its analyte. The following day, 96 µL of an
extension mix was added to each well of the incubation plate and, within five minutes, transferred to
a preprogrammed thermocycler for the extension step. For the detection step, 5 µL of each primer
(provided on a primer plate) was loaded onto a primed 96 by 96 Dynamic Array Integrated Fluidic
Circuit (IFC) from Fluidigm (South San Francisco, CA, USA). Lastly, 2.8 µL of the extension products
were combined with 7.2 µL of detection mix and 5 µL was loaded onto the primed chip. The chip was
loaded in the Fluidigm IFC Controller HX and the Olink Protein Expression 96 × 96 Program was run
on the Fluidigm’s Biomark HD System.
2.6. Functional Enrichment and Network Analyses
The biological impacts of MMD-associated circulating miRNAs were assessed by using validated
miRNA–mRNA interactions from miRTarBase database (mirtarbase.mbc.nctu.edu.tw) [30,31] instead of
predicted miRNA–mRNA integrations. Functional enrichment analyses were conducted with Database
for Annotation, Visualization, and Integrated Discovery (DAVID) [32]. The Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway information were used to generate the network with
Cytoscape [33,34].
3. Results
3.1. Characterization of miRNA in Whole Plasma, EVs and EV-Depleted Plasma
Approximately 8 million raw reads were obtained in whole plasma, EVs and EV-depleted plasma
samples (Table 1). Adapter trimming and removal of short (<15 nt) or low-quality reads resulted in an
average of 5 million reads/sample in whole plasma, 4.2 million in EVs and 4.8 million in EV-depleted
plasma (Table 1). No significant differences in raw and trimmed read counts were observed between
samples from MMD patients and controls. On average, the number of reads mapped to miRNAs
was highest in whole plasma samples and lowest in EVs. EV fractions also had the lowest number of
observed miRNA (having at least one mapped read without any nucleotide mismatch) and detectable
miRNA (having at least 10 mapped reads). Among the detectable miRNAs, 168 are in common in all
three sample types (whole plasma, EVs and EV-depleted plasma) from MMD patients and controls
(Figure S1). The overall miRNA profile between whole plasma and EV-depleted plasma is more similar
than EVs (Figure S2), which is in agreement with a prior report [35]. The top 10 and top five most
abundant miRNAs are similar amongst all three sample types (Table S3).
Table 1. Summary of small RNA sequencing results.
Category (mean) Whole Plasma Extracellular Vesicle (EV) EV-Depleted Plasma
Moyamoya Control Moyamoya Control Moyamoya Control
Raw read count 8,275,547 8,843,102 7,771,542 8,907,214 8,160,659 7,942,143
Trimmed read count 4,962,493 5,229,659 4,134,795 4,165,114 4,232,272 5,505,643
Mapped reads 686,951 672,717 64,844 68,817 191,987 497,845
Observed miRNA
(at least one mapped read) 598 574 384 366 467 497
Detected miRNA
(at least 10 mapped reads) 333 333 225 233 234 276
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3.2. Circulating miRNAs Associated with MMD
Even though the overall profiles of miRNA are similar across all samples, a subset of miRNAs
showed concentration differences between MMD patients and controls (Figure 1 and Table 2). To assess
the accuracy of NGS-based miRNA measurement, the concentration changes of select MMD-affected
miRNAs were verified using qPCR (Figure 2).
Table 2. List of moyamoya-affected miRNAs.
Sample Type miRNA ID
Moyamoya/Control
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represents the fold changes in either cycle number (qPCR) or log2-transformed reads per million 
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Figure 2. Comparison of miRNA concentration changes measured by qPCR (gray bars) and small RNA
sequencing (black bars). The X-axis indicates the identity of affected miRNA, and the Y-axi repre ents
the fold changes in either cycle number (qPCR) or log2-transformed reads per llion (RPM)-adjusted
small RNAseq rea ou ts. The sample types—whole plasma, EVs and EV-deplet d plasma—are
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The miRNA profiles of EVs and EV-depleted plasma were also compared to determine which
miRNA species are preferentially packaged in the vesicles. Of the 176 miRNAs showing significant
concentration differences between the two compartments inside of EVs (EV fraction) and outside
of EVs (EV-depleted plasma) (>1.5 fold concentration change, p-value < 0.05), only 38 had higher
concentrations in vesicles (Table S4). MMD status showed no impact on the overall miRNA distribution
between inside and outside of EVs. Analyzing the nucleotide composition of these 176 miRNAs
revealed an even distribution of four ribonucleotides for miRNAs preferentially located outside
of EVs (from EV-depleted plasma) and a higher fraction of “U” and lower fraction of “C” in the
EV-encapsulated miRNAs (Figure S3).
3.3. Biological Function Associated with MMD-Affected miRNAs
Using mRNA targets demonstrated by at least two different experimental methods (obtained
from miRTarBase), the MMD-affected circulating miRNAs may be involved in a number of biological
functions including pathways associated with immune response, cell growth and differentiation, signal
transduction and nervous system (Table S5). In MMD patients, abnormal angiogenesis and altered
levels of angiogenic factors in circulation have been reported [10]. A number of angiogenesis-related
biological processes and genes are also targeted by the MMD-affected circulating miRNAs. For example,
Angiogenin (ANG), a potent mediator of new blood vessel formation, is targeted by miR-409-3p (whole
plasma) and miR-223-5p (EV-depleted plasma). The detailed miRNA–mRNA interactions for genes
associated with the VEGF pathway are shown in Figure 3.
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Figure 3. Schematic diagram of mRNA-miRNA interactions associated with the vascular endothelial
growth factor (VEGF) signaling pathway. The network is built based on the VEGF signaling pathway
map (hsa04370) from the Kyoto Encyclopedia of Genes and Genomes (KEGG), identified by enrichment
analysis of miRNA targets. The genes are represented by circles and miRNAs are by squares (whole
plasma), triangles (EV) and diamonds (EV-depleted plasma). The identity of genes and miRNAs
involved in the process are indicated. The miRNA concentration changes in MMD patients are reflected
by either red- (increased concentration in MMD) or green- (decreased concentration in MMD) filled
shapes. The miRNA–mRNA interactions are based on validated gene targets from miRTarBase and
indicated by light blue lines.
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3.4. Impact of MMD on Plasma Proteome
We identified and quantified 529 proteins with iTRAQ. The results showed that MMD has
very little impact on the plasma proteome, and only two proteins, Apolipoprotein A IV (APOA4)
and Alkaline phosphatase (ALPL) showed statistically significant concentration changes (>1.5 fold
concentration difference with a p-value < 0.05 based on unpaired simple t test) (Figure 4A). We also
measured 92 inflammation-related proteins in patient plasma using PEA (Table S2). Comparing MMD
patient and control plasma samples, C-X-C motif chemokine 9 (CXCL9), Tumor necrosis factor receptor
superfamily member 9 (TNFRSF9), and TNF-related activation-induced cytokine (TNFSF11) showed
significant concentration differences (Figure 4B–D).
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tags for relative and absolute quantitation (iTRAQ) (A) or proximity extension assay (PEA) (B–D).
For iTRAQ, the protein identities are indicated on the X-axis, the p-values and sample groups are
indicated on top of the bar graph. For PEA data, sample groups are indicated on the X-axis and the
protein abundance is indicated on Y-axis. The protein identity is indicated on top of the figures.
3.5. RNF213 Mutation Affects Plasma Protein and miRNA Concentrations
Since the mutation status of the RNF213 gene for MMD patients in this study has been determined
(Table S1), we examined the impact of RNF213 mutation on protein and miRNA profiles in MMD patient
plasma. Several miRNAs showed concentration differences associated with the RNF213 mutations in
whole plasma, EVs and EV-depleted plasma (Table 3). Yet hsa-miR-574-3p in EV-depleted plasma is
the only miRNA that was also identified as a MMD-affected miRNA (Table 2). Even though the list of
RNF213 mutation-affected miRNAs are different from MMD-affected miRNAs, the pathways targeted
by these two sets of miRNAs are similar (Table S6). We did not detect any enriched pathways from
RNF213 mutation-associated miRNAs in whole plasma. One of the controls (individual #10-2) actually
is a carrier of the p.R4810K mutation; however, we did not observe the individual’s blood protein and
circulating miRNA profiles showed higher similarity to MMD patients including patients, SN10 and
SN10-4, within the family.
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Table 3. miRNAs showing concentration affected by RNF213 mutations among MMD patients.
Sample Type miRNA ID
Mutated/Wildtype















































On the plasma proteome, three plasma proteins, interleukin-17 receptor C (IL17RC),
transmembrane protease serine 4 (TMPRSS4), and copper chaperone for superoxide dismutase
(CCS) showed significant concentration differences between MMD patients with and without a RNF213
mutation based on the iTRAQ data (Figure 5A). From the PEA results, FGF19 and MMP10 showed
significant concentration changes associated with RNF213 mutation status (Figure 5B,C).
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4. Discussion
MMD is a rare inheritable disease with vascular pathologies. Mutations in several genes, including
RNF213 and ACTA2, have been linked to the disease [6,8]. The RNF213 transcript encodes a C3HC4-type
Zn-finger protein with ATPase and E3 ligase activities [36]; it targets filamin A (FLNA) and Nuclear
Factor of Activated T Cells 2 (NFATC2) to attenuate non-canonical Wnt signaling during vascular
development [37]. It may also regulate angiogenic factors, including several MMPs, and endothelial cell
proliferation [10,38]. Seven out of 12 patients who participated in this study have an RNF213 mutation.
Since vascular pathologies are the hallmarks of MMD, we conducted comprehensive analyses to assess
the i pact of MMD and RNF213 mutation status on the profiles of plasma protein and circulating
miRNA. Since RNAs in plasma are “packaged” in two major compartments, lipid vesicle encapsulated
and protein complexed, in addition to whole plasma, we also characterized the RNA in EVs (vesicle
encapsulated) f om plasma, and EV-depl ted plasma (ou side of EV protein-associated RNAs). Several
MMD-associated miRNAs in whole plasma, EVs and EV-depleted plas a were identifi d. Interestingly,
there are few ov rlapping miRNAs w th prio studies on moyamoya-associated circulating miRNA
changes [39,40]. This difference was probably caused by differ nt sample types, measurement platforms
and NGS library construction methods used in this study. In a study characterizing MMD plasma
J. Clin. Med. 2019, 8, 1648 11 of 15
samples by microarray and qPCR, the authors validated two up-regulated miRNAs, hsa-miR-6722-3p
and hsa-miR-328-3p [40]. Our sequencing analysis did not detect miR-6722-3p, but miR-328-3p showed
an increased concentration in EV-depleted plasma from MMD patients (Table 2).
Reports have shown changes to the circulating miRNA spectrum after ischemic stroke [41]. Since
one of the major symptoms for patients with MMD is ischemia, the MMD-affected circulating miRNAs
may share commonalities with miRNAs associated with ischemic stroke. Indeed, there are some
MMD-affected miRNAs, such as miR-27a-3p, that have also been observed in patients with ischemic
stroke [42]. Although MMD is a large artery disease [43], the vascular events caused by MMD are
usually lacunes in deeply located arterioles in basal ganglia and other subcortical regions. Similar to
MMD, cerebral small vessel disease (CSVD) is also characterized by lacunes in deeply located arterioles,
in basal ganglia and other subcortical regions. In a recent study, phosphodiesterase 3 (PDE3) was
found to play a role in endothelial function and vascular integrity, which was associated with the
susceptibility of CSVD. Furthermore, the miR-27a-3p significantly reduced the PDE3 level [44].
Levels of miR-9-5p and miR-124-3p, two brain-enriched miRNAs, are decreased in patients with
acute ischemic stroke [45]. We have also observed a decrease in miR-9-5p level in EVs from MMD
patients. The overall sequence reads mapped to miR-124-3p in our NGS results were too low to obtain
reliable data. Another NGS study using CSF from patients with small artery occlusion showed a
significant increase in miR-9-5p compared to controls [46]. The opposing direction of concentration
change between CSF and EVs may be a result of the blood–brain barrier blocking miRNA complexes
from entering the blood stream.
Changes to the plasma proteome in MMD patients were assessed by both iTRAQ and PEA.
The PEA dataset revealed a decrease in CXCL9 and increase in TNFSF11 and TNFRSF9 plasma
concentrations in patients with MMD. The three proteins are all involved in T-cell trafficking and
activation. CXCL9 is a T-cell chemoattractant and closely related to CXCL10 and CXCL11—both of
which showed concentration decreases in MMD patients but did not meet the statistical filtering for
MMD-affected proteins (>1.5 fold concentration changes, p-value < 0.05). TNFSF11 and TNFRSF9
proteins are members of TNF and TNF-receptor families and are involved in T-cell development
and activation. The changes of T-cell function-related proteins suggest the possible involvement of
T-cell immunity in MMD pathologies [6,47]. We did not observe significant concentration changes
between MMD and control plasma samples in the angiogenic proteins included in the PEA panel.
Using validated miRNA–mRNA interactions from miRTarBase [30,31], we did not observe connections
between MMD-affected circulating miRNAs and plasma proteins. This is not surprising since the
protein and miRNA in circulation may come from different cell types and/or organs in the body.
More than 50% of our MMD patients (seven out of 12) carry a RNF213 mutation (Table S1). Recent
reports have demonstrated the association of p.R4810K with the susceptibility of high blood pressure
and coronary heart diseases (CHD) [48–50]. Our blood proteome and miRNA analyses identified
several RNF213 mutation-associated changes; for example, the increase in the concentration of a
heart-enriched miRNA miR-499a-5p in MMD patient plasma (Table 2).
Our study is the first to analyze the changes of circulating miRNA inside and outside of EVs
associated with MMD. The miRNA profiling results showed a striking difference in the spectrum of
MMD-associated miRNAs between inside and outside of EVs. All EV-encapsulated MMD-affected
miRNAs showed a decreased concentration. In contrast, the concentrations of all the miRNAs except
miR-223-5p were increased in EV-depleted plasma. Even though most of the molecular processes
associated with affected miRNAs are similar in the three groups, the p-values are lower in EVs.
Analyzing the miRNA in both EVs and EV-depleted plasma showed that there are more miRNAs
outside of EVs (in EV-depleted plasma) and the overall profile of miRNA is different between the two
compartments. There are several known processes for cells to sort miRNAs into EVs, especially for
exosomes. These include processes mediated by neural sphingomyelinase 2 (nSMase2) protein [51],
AGO2 protein [52], miRNAs with uridine (U) at 3’ end [53], and a sequence motif, GGAG, recognized by
sumoylated heterogeneous nuclear ribonucleoproteins (hnRNPs) [54]. It is unclear whether the nSMase
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2- and AGO2-mediated miRNA sorting are based on specific sequence motif(s). Examining the miRNA
sequences between EVs and EV-depleted fractions from our data failed to identify common sequence
motif(s) including the reported exosomal miRNA-associated motif GGAG [54]. Since the small RNA
sequencing libraries were constructed with adapters containing four degenerated nucleotides (4Ns)
at ends, it is difficult for us to examine the non-template addition of nucleotide(s) at the 3’ end of
miRNA. However, the miRNAs showing higher concentrations in EVs have a higher percent of U
compared to the EV-depleted fraction (Figure S3), which is similar to our prior study on pre-term birth
patient samples [26]. This suggests that some miRNAs showed higher concentrations in EVs and these
miRNAs are preferentially packaged into EVs by processes yet to be determined.
In conclusion, we provide results from the first systematic analysis on the impact of MMD and
RNF213 mutations on the profiles of cell-free miRNA and protein in patient plasma samples. The
levels of selected MMD-affected miRNAs in the whole plasma, EVs, and EV-depleted plasma have
been confirmed by real-time qPCR. We showed that EV-encapsulated miRNA may better reflect the
pathology and could provide a noninvasive source of biomarkers to assess the progression of MMD.
However, due to the rareness of the disease, the number of patients available for this study and the
lack of validation cohort limits the applicability of our findings. Even though we characterized the
impact of RNF213 mutation status on miRNA and protein in circulation, due to the large RNF213 gene,
patients might also carry mutations other than the p.R4810K which might also impact the miRNA and
protein profiles in plasma. This study used family member as a control, and this is not ideal since age
difference may have impact on the miRNA and protein profiles. However, using family member as a
control can significantly reduce the contribution of genetic and environmental factors, since those are
known to contribute to various cerebrovascular diseases. Due to unwillingness, Magnetic Resonance
Angiography (MRA) was not performed on all unaffected family members, which also limits the
application of MMD-associated miRNAs and proteins. A study with a larger patient cohort with a
well-characterized mutation status for the RNF213 gene and proper controls is critically needed to
validate the findings and assess its potential applications.
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